Misonix to Participate in Upcoming May and June Virtual Investor Conferences
Misonix, Inc. (NASDAQ: MSON) announced that CEO Stavros Vizirgianakis and CFO Joe Dwyer will participate in upcoming virtual investor conferences in May and June 2021. Key events include the Canaccord Genuity Virtual Musculoskeletal Conference on May 20, UBS Global Healthcare Conference on May 25, and the 18th Annual Craig-Hallum Institutional Investor Conference on June 2. A live webcast of the UBS event will be accessible on Misonix's website. Investors can schedule one-on-one meetings with management, with further details available through the investor relations contact.
- None.
- None.
FARMINGDALE, N.Y., May 10, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that Chief Executive Officer, Stavros Vizirgianakis, along with Chief Financial Officer, Joe Dwyer, will be participating in the following upcoming virtual investor conferences in May and June:
- Canaccord Genuity Virtual Musculoskeletal Conference
Date: Thursday, May 20, 2021
Virtual Presentation: 2:30 p.m. ET
- UBS Global Healthcare Conference
Date: Tuesday, May 25, 2021
Virtual Presentation: 5:00 p.m. ET
A live webcast of the UBS Global Healthcare Conference fireside chat presentation will be available at the Company’s website through the “Events and Presentations” section under “Investor Relations” at www.misonix.com. A replay of the webcast will be available on the Company’s website for 30 days.
- 18th Annual Craig-Hallum Institutional Investor Conference
Date: Wednesday, June 2, 2021
Management will be available to host one-on-one or small group meetings with investors who are registered to attend the conferences.
For more information about the conferences or to schedule a virtual one-on-one meeting with management, please contact your conference representative. Alternatively, please contact Misonix’s investor relations firm, JCIR, at mson@jcir.com.
About Misonix, Inc.
Misonix, Inc. (Nasdaq: MSON) is a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products. Its surgical team markets and sells BoneScalpel and SonaStar, which facilitate precise bone sculpting and removal of soft and hard tumors and tissue, primarily in the areas of neurosurgery, orthopedic, plastic and maxillo-facial surgery. The Company's wound team markets and sells TheraSkin, Therion, TheraGenesis and SonicOne to debride, treat and heal chronic and traumatic wounds in inpatient, outpatient and physician office sites of service. At Misonix, Better Matters! That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve outcomes for patients. Additional information is available on the Company's web site at www.misonix.com.
| Contact: | Norberto Aja, Jennifer Neuman |
| Joe Dwyer | JCIR |
| Chief Financial Officer | 212-835-8500 or mson@jcir.com |
| Misonix, Inc. | |
| 631-927-9113 |
FAQ
What are the upcoming investor conferences for Misonix (MSON) in May and June 2021?
What time will Misonix present at the UBS Global Healthcare Conference?
Will Misonix provide a webcast of their presentations?
How can investors meet with Misonix management during the conferences?
Who should be contacted for more information regarding Misonix's investor conferences?
